<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37349634</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Trends in mortality in patients with systemic autoimmune rheumatic diseases (SARD) during the COVID-19 pandemic in Mexico.</ArticleTitle><Pagination><StartPage>1611</StartPage><EndPage>1619</EndPage><MedlinePgn>1611-1619</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-023-05371-w</ELocationID><Abstract><AbstractText>The study aimed to analyze the influence of the COVID-19 pandemic on mortality rates in patients with systemic autoimmune rheumatic diseases (SARD) in Mexico. We selected SARD-related deaths using National Open Data and Information from the Ministry of Health, Mexico, and ICD-10 codes. We assessed the observed compared to the predicted mortality values for 2020 and 2021, employing trends from 2010 to 2019 with joinpoint and prediction modelling analyses.&#xa0;Among 12,742 deaths due to SARD between 2010 and 2021, the age-standardized mortality rate (ASMR) increased significantly between 2010 and 2019 (pre-pandemic) (annual percentage change [APC] 1.1%; 95% CI 0.2-2.1), followed by a non-significant decrease during the pandemic period (APC 13.9%; 95% CI 13.9-5.3). In addition, the observed ASMR of 1.19 for 2020 for SARD and of 1.14 for 2021 were lower than the predicted values of 1.25 (95% CI 1.22-1.28) for 2020 and 1.25 (95% CI 1.20-1.30) for 2021. Similar findings were identified for specific SARD, mainly systemic lupus erythematosus (SLE), or by sex or age group. Interestingly, the observed mortality rates for SLE in the Southern region of 1.00 in 2020 and 1.01 in 2021 were both significantly greater than the predicted values of 0.71 (95% CI 0.65-0.77) in 2020 and 0.71 (95% CI 0.63-0.79).&#xa0;In Mexico, the observed SARD mortality rates were not higher than the expected values during the pandemic, except for SLE in the Southern region. No differences by sex or age group were identified.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mungu&#xed;a-Realpozo</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6967-7939</Identifier><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Research Unit, Specialties Hospital UMAE-CIBIOR, Instituto Mexicano del Seguro Social, Puebla, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Medicine School, Benem&#xe9;rita Universidad Aut&#xf3;noma de Puebla, Calle 13 Sur 2702, Los Volcanes, 72420, Puebla, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mendoza-Pinto</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5101-7705</Identifier><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Research Unit, Specialties Hospital UMAE-CIBIOR, Instituto Mexicano del Seguro Social, Puebla, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Medicine School, Benem&#xe9;rita Universidad Aut&#xf3;noma de Puebla, Calle 13 Sur 2702, Los Volcanes, 72420, Puebla, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Etchegaray-Morales</LastName><ForeName>Ivet</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-5857-4299</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Medicine School, Benem&#xe9;rita Universidad Aut&#xf3;noma de Puebla, Calle 13 Sur 2702, Los Volcanes, 72420, Puebla, Mexico. ivetcheg@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solis-Poblano</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-0389-1825</Identifier><AffiliationInfo><Affiliation>Department of Haematology, Specialties Hospital UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ay&#xf3;n-Aguilar</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9704-8032</Identifier><AffiliationInfo><Affiliation>Coordinaci&#xf3;n M&#xe9;dica de Investigaci&#xf3;n en Salud, Instituto Mexicano del Seguro Social, Delegaci&#xf3;n Puebla, Puebla, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Lara</LastName><ForeName>Edith</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7624-3696</Identifier><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Research Unit, Specialties Hospital UMAE-CIBIOR, Instituto Mexicano del Seguro Social, Puebla, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orbe-Sosa</LastName><ForeName>Jacsiry</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0006-4442-7833</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Medicine School, Benem&#xe9;rita Universidad Aut&#xf3;noma de Puebla, Calle 13 Sur 2702, Los Volcanes, 72420, Puebla, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;ndez-Mart&#xed;nez</LastName><ForeName>Socorro</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7463-0580</Identifier><AffiliationInfo><Affiliation>Coordinaci&#xf3;n de Planeaci&#xf3;n y Enlace Institucional, Instituto Mexicano del Seguro Social, Delegaci&#xf3;n Puebla, Puebla, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Carrasco</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1696-9871</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Medicine School, Benem&#xe9;rita Universidad Aut&#xf3;noma de Puebla, Calle 13 Sur 2702, Los Volcanes, 72420, Puebla, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-standardized mortality rate</Keyword><Keyword MajorTopicYN="N">Annual percentage change</Keyword><Keyword MajorTopicYN="N">COVID-19 pandemic</Keyword><Keyword MajorTopicYN="N">Systemic autoimmune rheumatic diseases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37349634</ArticleId><ArticleId IdType="doi">10.1007/s00296-023-05371-w</ArticleId><ArticleId IdType="pii">10.1007/s00296-023-05371-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sarzi-Puttini P, Ceribelli A, Marotto D et al (2019) Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev 18:583&#x2013;592. https://doi.org/10.1016/j.autrev.2018.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.12.009</ArticleId><ArticleId IdType="pubmed">30959214</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Wang B, Fan S et al (2022) Global burden of musculoskeletal disorders and attributable factors in 204 countries and territories: a secondary analysis of the Global Burden of Disease 2019 study. BMJ Open 12:e062183. https://doi.org/10.1136/bmjopen-2022-062183</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-062183</ArticleId><ArticleId IdType="pubmed">35768100</ArticleId><ArticleId IdType="pmc">9244680</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Etchegaray I, Garcia-Carrasco M, Mungu&#xed;a-Realpozo P et al (2021) Changing trends in rheumatoid arthritis mortality in Mexico, from 1998 to 2017. Rheumatol Int 41:2225&#x2013;2231. https://doi.org/10.1007/s00296-021-05013-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-05013-z</ArticleId><ArticleId IdType="pubmed">34609597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza-Pinto C, Etchegaray-Morales I, Garcia-Carrasco M et al (2022) Twenty-year trends in all-cause mortality of patients with systemic lupus erythematosus in Mexico: results from a nationwide health registry. Lupus 31:382&#x2013;391. https://doi.org/10.1177/09612033221078228</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221078228</ArticleId><ArticleId IdType="pubmed">35188438</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Carrasco M, Mendoza-Pinto C, Etchegaray-Morales I et al (2022) Temporal trends in mortality in patients with systemic sclerosis in public hospitals across Mexico from 1998&#x2013;2017. Arch Med Res 53:610&#x2013;616. https://doi.org/10.1016/j.arcmed.2022.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2022.07.005</ArticleId><ArticleId IdType="pubmed">36038446</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza-Pinto C, Etchegaray-Morales I, Mungu&#xed;a-Realpozo P et al (2022) Trends in all-cause hospitalizations for systemic lupus erythematosus in Mexico, 2000&#x2013;2019. Lupus 31:1679&#x2013;1684. https://doi.org/10.1177/09612033221128745</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221128745</ArticleId><ArticleId IdType="pubmed">36128770</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone T, Picerno V, Pafundi V et al (2022) Impact of the COVID-19 pandemic on the appropriateness of diagnostic pathways of autoimmune rheumatic diseases. J Rheumatol 49:219&#x2013;224. https://doi.org/10.3899/jrheum.210611</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.210611</ArticleId><ArticleId IdType="pubmed">34654735</ArticleId></ArticleIdList></Reference><Reference><Citation>George MD, Venkatachalam S, Banerjee S et al (2021) Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic. J Rheumatol 48:603&#x2013;607. https://doi.org/10.3899/JRHEUM.201017</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/JRHEUM.201017</ArticleId><ArticleId IdType="pubmed">33191284</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco MA, Leykina LA, Izadi Z et al (2021) Association of race and ethnicity with COVID-19 outcomes in rheumatic disease: data from the COVID-19 global rheumatology alliance physician registry. Arthritis Rheumatol 73:374&#x2013;380. https://doi.org/10.1002/art.41567</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41567</ArticleId><ArticleId IdType="pubmed">33146001</ArticleId><ArticleId IdType="pmc">8467766</ArticleId></ArticleIdList></Reference><Reference><Citation>Datos abiertos. Secretar&#xed;a de Salud/Direcci&#xf3;n General de Informaci&#xf3;n en Salud. http://www.dgis.salud.gob.mx/contenidos/basesdedatos/Datos_Abiertos_gobmx.html . Accessed 1 Dec 2022</Citation></Reference><Reference><Citation>Consejo Nacional de Poblaci&#xf3;n. Proyecciones de la poblaci&#xf3;n de M&#xe9;xico, 1950&#x2013;2050 (CONAPO 2020). http://www.conapo.gob.mx/es/CONAPO/Proyecciones . Accessed 20 Nov 2022</Citation></Reference><Reference><Citation>Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335&#x2013;351. https://doi.org/10.1002/(sici)1097-0258(20000215)19:3%3c335::aid-sim336%3e3.0.co;2-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-0258(20000215)19:3&lt;335::aid-sim336&gt;3.0.co;2-z</ArticleId><ArticleId IdType="pubmed">10649300</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezende RPV, Mendon&#xe7;a de Santana F, Figueiredo CP (2022) Unchanged trend in mortality from systemic lupus erythematosus during the 2020 COVID-19 pandemic: a nationwide population-based study. Lupus 31:1020&#x2013;1022</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221098540</ArticleId><ArticleId IdType="pubmed">35486106</ArticleId><ArticleId IdType="pmc">9086209</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, He X, Lee EY et al (2023) Excess psoriasis and psoriatic arthritis mortality during the COVID-19 pandemic in the United States: a nationwide population-based study from 2010 to 2021. J Eur Acad Dermatology Venereol 37:1221&#x2013;1227. https://doi.org/10.1111/jdv.18978</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.18978</ArticleId></ArticleIdList></Reference><Reference><Citation>2023 E 137 published 06 A Weekly epidemiological update on COVID-19 - 6 April 2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-april-2023 . Accessed 20 Apr 2023</Citation></Reference><Reference><Citation>Antonio-Villa NE, Bello-Chavolla OY, Ferm&#xed;n-Mart&#xed;nez CA et al (2022) Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico. Int J Epidemiol 51:1711&#x2013;1721. https://doi.org/10.1093/ije/dyac184</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac184</ArticleId><ArticleId IdType="pubmed">36174226</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Guerrero VM, Beltr&#xe1;n-S&#xe1;nchez H (2021) Heterogeneity in excess mortality and its impact on loss of life expectancy due to COVID-19: evidence from Mexico. Can Stud Popul 48:165&#x2013;200. https://doi.org/10.1007/s42650-021-00051-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42650-021-00051-1</ArticleId><ArticleId IdType="pubmed">34667369</ArticleId><ArticleId IdType="pmc">8516578</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L (2016) The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol 34:21&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">27586799</ArticleId></ArticleIdList></Reference><Reference><Citation>Manry J, Bastard P, Gervais A et al (2022) The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A 119:e2200413119. https://doi.org/10.1073/pnas.2200413119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2200413119</ArticleId><ArticleId IdType="pubmed">35576468</ArticleId><ArticleId IdType="pmc">9173764</ArticleId></ArticleIdList></Reference><Reference><Citation>Larionova R, Byvaltsev K, Kravtsova O et al (2022) SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases. J Transl Autoimmun 5:100154. https://doi.org/10.1016/j.jtauto.2022.100154</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2022.100154</ArticleId><ArticleId IdType="pubmed">35434592</ArticleId><ArticleId IdType="pmc">9005220</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfa;a-Figueroa &#xcd;, L&#xf3;pez-Longo J, Galindo-Izquierdo M et al (2017) Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum 47:38&#x2013;45. https://doi.org/10.1016/j.semarthrit.2017.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2017.01.010</ArticleId><ArticleId IdType="pubmed">28259425</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacio-Mej&#xed;a LS, Hern&#xe1;ndez-&#xc1;vila JE, Hern&#xe1;ndez-&#xc1;vila M et al (2022) Leading causes of excess mortality in Mexico during the COVID-19 pandemic 2020&#x2013;2021: a death certificates study in a middle-income country. Lancet Reg Heal Am 13:100303. https://doi.org/10.1016/j.lana.2022.100303</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100303</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoff LS, Ravichandran N, Shinjo SK et al (2023) COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 vaccination in autoimmune diseases. Rheumatol Int 43:47&#x2013;58. https://doi.org/10.1007/s00296-022-05229-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05229-7</ArticleId><ArticleId IdType="pubmed">36271958</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-&#xc1;vila DG, Barahona-Correa J, Romero-Alvernia D et al (2022) Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. Rheumatol Int 42:41&#x2013;49. https://doi.org/10.1007/s00296-021-05014-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-05014-y</ArticleId><ArticleId IdType="pubmed">34739574</ArticleId></ArticleIdList></Reference><Reference><Citation>International Classification of Diseases (ICD). https://icd.who.int/browse10/2010/en#/ . Accessed 10 Jan 2023</Citation></Reference><Reference><Citation>Raymond WD, Lester S, Preen DB et al (2021) Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study. Lupus Sci Med 8:e000539. https://doi.org/10.1136/lupus-2021-000539</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000539</ArticleId><ArticleId IdType="pubmed">34667085</ArticleId><ArticleId IdType="pmc">8527118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerola AM, Kazemi A, Rollefstad S et al (2022) All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology 61:4656&#x2013;4666. https://doi.org/10.1093/rheumatology/keac210</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac210</ArticleId><ArticleId IdType="pubmed">35377442</ArticleId><ArticleId IdType="pmc">9707036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagni F, Simon D, Tascilar K et al (2021) COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 3:e724&#x2013;e736. https://doi.org/10.1016/S2665-9913(21)00247-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00247-2</ArticleId><ArticleId IdType="pubmed">34485930</ArticleId><ArticleId IdType="pmc">8397302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>